Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
2019 Fourth Annual Oncology Guide to New FDA Approvals - Drug Updates, FDA Approvals, Prostate Cancer
Prostate cancer, the second most common type of cancer in men, is expected to affect 11.6% of all men during their lifetime. In fact, more than 3 million men in the United States are living with prostate cancer. It is estimated that in 2017, 161,360 men were newly diagnosed with prostate cancer, and 26,730 men died from the disease.
Prostate cancer is the third most common type of cancer in the United States, after breast cancer and lung cancer. In 2018 alone, 164,690 individuals were diagnosed with prostate cancer, accounting for nearly 10% of all new cancer cases, and 29,430 deaths were attributed to the disease. Prostate cancer is most frequently diagnosed in men aged 65 to 74 years (median age, 66 years). More than 98% of patients with prostate cancer survive ≥5 years; however, the 5-year survival rate drops to 30% for patients with metastatic disease.
- How Oncology Pharmacists Can Enhance Patient Quality of Care
- Metastasis-Free Survival for Prostate Cancer Longerwith Apalutamide than with Placebo
- Nivolumab plus Ipilimumab Combination Improves Overall Survival in Untreated Renal-Cell Carcinoma
Results 1 - 3 of 3